Table 4.
RBD-specific IgG antibodies and pseudovirus-neutralizing antibodies to Omicron BA.4/5 before and after booster vaccination
| Variable | Inactivated vaccine | Ad5-nCoV | ||||||
|---|---|---|---|---|---|---|---|---|
| Day 0 (n = 99a) | Day 14 (n = 99a) | Day 28 (n = 98a) | Day 90 (n = 97a) | Day 0 (n = 100) | Day 14 (n = 100) | Day 28 (n = 99a) | Day 90 (n = 98a) | |
| Anti-RBD-IgG | ||||||||
| GMT | 63.1 (48.1–82.7) | 263.3 (191.0–292.4) | 170.5 (138.6–209.8) | 106.7 (83.7–135.9) | 64.7 (50.7–82.7) | 2250 (1806.0–2803.0) | 1594 (1284.0–1979.0) | 993.2 (786.4–1254.0) |
| GMC (RU/mL) | 119.1 (69.9–168.2) | 333.3 (247.8–418.8) | 234.4 (182.6–286.2) | 152.7 (104.7–200.7) | 105.2 (77.5–132.8) | 2924.0 (2305.0–3542.0) | 2142.0 (1649.0–2635.0) | 1275.0 (868.3–1681.0) |
| Seropositive rate (%) | 52.5 (42.2–62.7) | 93.9 (87.3–97.7) | 90.8 (83.2–95.7) | 76.3 (66.6–84.3) | 55.0 (44.7–65.0) | 100.0 (96.4–100.0) | 100.0 (96.3–100.0) | 100.0 (96.3–100.0) |
| Seroconversion rate (%) | NA | 37.4 (27.9–46.7) | 27.6 (19.0–37.5) | 5.2 (1.7–11.6) | NA | 91.0 (83.6–95.8) | 88.9 (81.0–94.3) | 71.4 (61.4–80.1) |
| GMFI | NA | 3.7 (3.0–4.6) | 2.7 (2.2–3.4) | 1.7 (1.4–2.1) | NA | 34.8 (26.5–45.7) | 25.0 (19.0–32.8) | 9.1 (7.0–11.8) |
| Neutralizing antibodies to Pseudovirus (BA.4/5) | ||||||||
| GMT | 34.1 (31.0–37.4) | 65.5 (58.1–76.0) | 51.7 (45.1–59.2) | 31.9 (27.7–36.8) | 30.0 (27.2–33.1) | 228.9 (187.4–279.5) | 162.1 (131.7–199.6) | 99.8 (82.8–120.2) |
| Seropositive rate (%) | 4.0 (1.1–10.0) | 34.3 (25.1–44.6) | 26.5 (18.1–36.4) | 8.2 (3.6–15.6) | 1.0 (0.02–5.4) | 79.0 (69.7–86.5) | 74.7 (65.0–82.9) | 61.2 (50.8–70.9) |
| Seroconversion rate (%) | NA | 17.2 (10.3–26.1) | 8.2 (3.6–15.5) | 0.0 (0.0–3.7) | NA | 74.0 (64.3–82.3) | 58.6 (48.2–63.4) | 38.8 (29.1–49.2) |
| GMFI | NA | 2.0 (1.7–2.3) | 1.1 (0.9–1.3) | 1.0 (0.8–1.1) | NA | 7.6 (6.3–9.3) | 5.4 (4.4–6.6) | 3.3 (2.7–4.0) |
Data are mean or geometric mean (95% CI) or n (%).
GMT geometric mean titer, GMC geometric mean concentration, GMFI geometric mean fold increase.
aDiscontinued: subjects failed to provide blood and therefore were not included in the antibody assay.